Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orla Maguire

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Scientific Reports|March 16, 2019
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Cell Reports|June 25, 2020
CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell SurvivalAdam Utley, Colin Chavel, Shivana Lightman, et al.
Journal for Immunotherapy of Cancer|November 14, 2023
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influxShipra Gandhi, Mateusz Opyrchal, Melissa J Grimm, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal CancerChristos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Cancer Cell|August 8, 2025
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinomaNicholas J Salgia, Adil Khan, Wilhelm M Aubrecht, et al.
European Journal of Immunology|October 22, 2019
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)Andrea Cossarizza, Hyun-Dong Chang, Andreas Radbruch, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Scientific Reports|March 16, 2019
Publisher Correction: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironmentShin La Shu, Yunchen Yang, Cheryl L Allen, et al.
Cell Reports|June 25, 2020
CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell SurvivalAdam Utley, Colin Chavel, Shivana Lightman, et al.
Journal for Immunotherapy of Cancer|November 14, 2023
Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influxShipra Gandhi, Mateusz Opyrchal, Melissa J Grimm, et al.
Carcinogenesis|May 15, 2010
Elevated NCOR1 disrupts PPARalpha/gamma signaling in prostate cancer and forms a targetable epigenetic lesionSebastiano Battaglia, Orla Maguire, James L Thorne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal CancerChristos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
International Journal of Cancer|March 7, 2026
TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumabChristos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, et al.
Cancer Cell|August 8, 2025
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinomaNicholas J Salgia, Adil Khan, Wilhelm M Aubrecht, et al.
European Journal of Immunology|October 22, 2019
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)Andrea Cossarizza, Hyun-Dong Chang, Andreas Radbruch, et al.
Pageof 4